XML 29 R19.htm IDEA: XBRL DOCUMENT
v3.23.2

Stockholders' Equity | 6 Months Ended
--- | ---
Jul. 01, 2023
Stockholders' Equity Note [Abstract] |
Stockholders' Equity | Stockholders’ Equity Common Stock: Our Articles of Incorporation authorize 200,000,000 shares of common stock that may be issued from time to time having such rights, powers, preferences, and designations as the Board of Directors may determine. During the 13 weeks ended July 1, 2023 and July 2, 2022, no shares of common stock were issued in lieu of professional services. On March 22, 2023, the Company entered into a Securities Purchase Agreement with certain institutional investors for the sale by the Company in a registered direct offering of 361,000 shares of the Company’s common stock, par value $0.001 per share, at a purchase price per share of Common Stock of $1.17. The offering closed on March 24, 2023. The aggregate gross proceeds for the sale of the shares of Common Stock were approximately $422,000, before deducting the placement agent fees and related expenses. The Company intends to use the net proceeds for working capital and general corporate purposes. As of July 1, 2023, and December 31, 2022, there were 3,768,878 and 2,827,410 shares, respectively, of common stock issued and outstanding. Stock Options: The 2016 Plan, which replaces the 2011 Plan, authorizes the granting of awards in any of the following forms: (i) incentive stock options, (ii) nonqualified stock options, (iii) restricted stock awards, and (iv) restricted stock units, and expires on the earlier of October 28, 2026, or the date that all shares reserved under the 2016 Plan are issued or no longer available. The 2016 Plan provides for the issuance of up to 800,000 shares of common stock pursuant to awards granted under the 2016 Plan. The vesting period is determined by the Board of Directors at the time of the stock option grant. As of July 1, 2023, and December 31, 2022, 100,000 and 90,000 options were outstanding under the 2016 Plan, respectively. The Company’s 2011 Plan, which has expired, authorizes the granting of awards in any of the following forms: (i) stock options, (ii) stock appreciation rights, and (iii) other share-based awards, including but not limited to, restricted stock, restricted stock units or performance shares. As of July 1, 2023, and December 31, 2022, 14,000 and 20,000 were outstanding under the 2011 Plan, respectively. No additional awards will be granted under the 2011 Plan. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model. There were 10,000 options granted during the 26 weeks ended July 1, 2023. Additional information relating to all outstanding options is as follows:
| Options Outstanding |  | Weighted Average Exercise Price |  | Aggregate Intrinsic Value |  | Weighted Average Remaining Contractual Life
Outstanding at January 1, 2022 | 117,500 |  | $ | 7.16 |  |  | $ | 21 |  |  | 7.0
Cancelled/expired | (7,500) |  | — |  |  |  |  |
Outstanding at December 31, 2022 | 110,000 |  | $ | 6.27 |  |  | $ | — |  |  | 6.5
Granted | 10,000 |  | 1.53 |  |  |  |  |
Cancelled/expired | (6,000) |  | $ | 9.45 |  |  |  |  |
Balance at July 1, 2023 | 114,000 |  | $ | 5.68 |  |  | $ | — |  |  | 6.6
Exercisable at July 1, 2023 | 111,000 |  | $ | 5.79 |  |  | $ | — |  |  | 6.6
The Company recognized approximately $4,000 and $1,000 of share-based compensation expense for the 13 weeks ended July 1, 2023 and July 2, 2022, respectively, and approximately $12,000 and $1,000 of share-based compensation expense for the 26 weeks ended July 1, 2023 and July 2, 2022, respectively. As of July 1, 2023, the Company has approximately $1,100 of unrecognized share-based compensation expense associated with stock option awards which the company expects to recognize as share-based compensation expense through Q3 2023. Series A-1 Preferred Stock Shares of Series A-1 Preferred Stock are convertible into the Company’s common shares at a ratio of 1:20. 12,882 shares were converted during the 26 weeks ended July 1, 2023 (see Note 12). As of July 1, 2023 and December 31, 2022, there were 209,706 and 222,588 shares of Series A-1 Preferred Stock outstanding, respectively.

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration